Metabolic effects of bile acids in the gut in health and disease

Current Medicinal Chemistry

Volumn 21, Issue 24, 2014, Pages 2822-2829

  Boesjes, Marije ^a   Brufau, Gemma ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bile acids; Gut; Microbiota

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENYLATE CYCLASE; BILE ACID; CELL NUCLEUS RECEPTOR; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLIC ACID; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLIC AMP; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HEPATOCYTE NUCLEAR FACTOR 4; LITHOCHOLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREGNANE X RECEPTOR; PROTEIN KINASE; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; UNSATURATED FATTY ACID; URSODEOXYCHOLIC ACID; VITAMIN D RECEPTOR;

ARTICLE; BACTERIAL MEMBRANE; BILE ACID METABOLISM; BILE ACID SYNTHESIS; BROWN ADIPOSE TISSUE; CHOLESTEROL METABOLISM; ENERGY EXPENDITURE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEPATITIS; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INTESTINE ABSORPTION; INTESTINE FLORA; LIPID DIET; LIVER FUNCTION; METABOLIC REGULATION; NEGATIVE FEEDBACK; NERVOUS SYSTEM; NONHUMAN; OXYGEN CONSUMPTION; PROTEIN EXPRESSION; PROTEIN SECRETION; PRURITUS; SIGNAL TRANSDUCTION; ANIMAL; DISEASES; HEALTH; INTESTINE; METABOLISM; MICROBIOLOGY; MICROFLORA;

ANIMALS; BILE ACIDS AND SALTS; DISEASE; HEALTH; HUMANS; INTESTINES; MICROBIOTA;

EID: 84903720102     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140303142053     Document Type: Article

References (89)

1. Makishima, M.; Okamoto, A. Y.; Repa, J. J.; Tu, H.; Learned, R. M.; Luk, A.; Hull, M. V.; Lustig, K. D.; Mangelsdorf, D. J.; Shan, B. Identification of a nuclear receptor for bile acids. Science, 1999, 284, 1362-1365. (Pubitemid 29289663)
2. Parks, D. J.; Blanchard, S. G.; Bledsoe, R. K.; Chandra, G.; Consler, T. G.; Kliewer, S. A.; Stimmel, J. B.; Willson, T. M.; Zavacki, A. M.; Moore, D. D.; Lehmann, J. M. Bile acids: natural ligands for an orphan nuclear receptor. Science, 1999, 284, 1365-1368. (Pubitemid 29289664)
3. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell., 1999, 3, 543-553.
4. Maruyama, T.; Miyamoto, Y.; Nakamura, T.; Tamai, Y.; Okada, H.; Sugiyama, E.; Nakamura, T.; Itadani, H.; Tanaka, K. Identification of membrane-type receptor for bile acids (M-BAR). Biochem. Biophys. Res. Commun., 2002, 298, 714-719.
5. Kawamata, Y.; Fujii, R.; Hosoya, M.; Harada, M.; Yoshida, H.; Miwa, M.; Fukusumi, S.; Habata, Y.; Itoh, T.; Shintani, Y.; Hinuma, S.; Fujisawa, Y.; Fujino, M. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem., 2003, 278, 9435-9440.
6. Wang, Y. M.; Ong, S. S.; Chai, S. C.; Chen, T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin. Drug Metab. Toxicol., 2012, 8, 803-817.
7. Rezen, T.; Rozman, D.; Pascussi, J. M.; Monostory, K. Interplay between cholesterol and drug metabolism. Biochim. Biophys. Acta, 2011, 1814, 146-160.
8. Wiggins, H. S.; Wootton, I. D. Studies in the bile acids. 3. The conjugated bile salts of certain primates. Biochem. J., 1958, 70, 349-352.
9. Hofmann, A. F. The enterohepatic circulation of conjugated bile acids in healthy man: quantitative description and functions. Expos. Annu. Biochim. Med., 1977, 33, 69-86.
10. Goodwin, B.; Jones, S. A.; Price, R. R.; Watson, M. A.; McKee, D. D.; Moore, L. B.; Galardi, C.; Wilson, J. G.; Lewis, M. C.; Roth, M. E.; Maloney, P. R.; Willson, T. M.; Kliewer, S. A. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell., 2000, 6, 517-526.
11. Lu, T. T.; Makishima, M.; Repa, J. J.; Schoonjans, K.; Kerr, T. A.; Auwerx, J.; Mangelsdorf, D. J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell., 2000, 6, 507-515.
12. Zhang, M.; Chiang, J. Y. L. Transcriptional Regulation of the Human Sterol 12alpha-Hydroxylase Gene (CYP8B1). Roles of hepatocyte nuclear factor-4alpha in mediating bile acid repression. J. Biol. Chem., 2001, 276, 41690-41699.
13. Chen, W.; Chiang, J. Y. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene, 2003, 313, 71-82.
14. Garuti, R.; Croce, M. A.; Piccinini, L.; Tiozzo, R.; Bertolini, S.; Calandra, S. Functional analysis of the promoter of human sterol 27-hydroxylase gene in HepG2 cells. Gene, 2002, 283, 133-143. (Pubitemid 34178517)
15. Yang, Y.; Zhang, M.; Eggertsen, G.; Chiang, J. Y. On the mechanism of bile acid inhibition of rat sterol 12alpha-hydroxylase gene (CYP8B1) transcription: roles of alpha-fetoprotein transcription factor and hepatocyte nuclear factor 4alpha. Biochim. Biophys. Acta, 2002, 1583, 63-73.
16. Lin, B. C.; Wang, M.; Blackmore, C.; Desnoyers, L. R. Liverspecific activities of FGF19 require Klotho beta. J. Biol. Chem., 2007, 282, 27277-27284.
17. Holt, J. A.; Luo, G.; Billin, A. N.; Bisi, J.; McNeill, Y. Y.; Kozarsky, K. F.; Donahee, M.; Wang, D. Y.; Mansfield, T. A.; Kliewer, S. A.; Goodwin, B.; Jones, S. A. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev., 2003, 17, 1581-1591. (Pubitemid 36828786)
18. Inagaki, T.; Choi, M.; Moschetta, A.; Peng, L.; Cummins, C. L.; McDonald, J. G.; Luo, G.; Jones, S. A.; Goodwin, B.; Richardson, J. A.; Gerard, R. D.; Repa, J. J.; Mangelsdorf, D. J.; Kliewer, S. A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab., 2005, 2, 217-225.
19. Keitel, V.; Cupisti, K.; Ullmer, C.; Knoefel, W. T.; Kubitz, R.; Haussinger, D. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology, 2009, 50, 861-870.
20. Keitel, V.; Gorg, B.; Bidmon, H. J.; Zemtsova, I.; Spomer, L.; Zilles, K.; Haussinger, D. The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. Glia, 2010, 58, 1794-1805.
21. Pols, T. W.; Nomura, M.; Harach, T.; Lo Sasso, G.; Oosterveer, M. H.; Thomas, C.; Rizzo, G.; Gioiello, A.; Adorini, L.; Pellicciari, R.; Auwerx, J.; Schoonjans, K. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell. Metab., 2011, 14, 747-757.
22. Sato, H.; Macchiarulo, A.; Thomas, C.; Gioiello, A.; Une, M.; Hofmann, A. F.; Saladin, R.; Schoonjans, K.; Pellicciari, R.; Auwerx, J. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J. Med. Chem., 2008, 51, 1831-1841.
23. Stacey, M.; Webb, M. Studies on the antibacterial properties of the bile acids and some compounds derived from cholanic acid. Proc. R. Soc. Med., 1947, 134, 523-537.
24. Islam, K. B.; Fukiya, S.; Hagio, M.; Fujii, N.; Ishizuka, S.; Ooka, T.; Ogura, Y.; Hayashi, T.; Yokota, A. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology, 2011, 141, 1773-1781.
25. Yokota, A.; Fukiya, S.; Islam, K. B.; Ooka, T.; Ogura, Y.; Hayashi, T.; Hagio, M.; Ishizuka, S. Is bile acid a determinant of the gut microbiota on a high-fat diet? Gut Microbes, 2012, 3, 455-459.
26. Kurdi, P.; Kawanishi, K.; Mizutani, K.; Yokota, A. Mechanism of growth inhibition by free bile acids in Lactobacilli and Bifidobacteria. J. Bacteriol., 2006, 188, 1979-1986. (Pubitemid 43346878)
27. Turnbaugh, P. J.; Hamady, M.; Yatsunenko, T.; Cantarel, B. L.; Duncan, A.; Ley, R. E.; Sogin, M. L.; Jones, W. J.; Roe, B. A.; Affourtit, J. P.; Egholm, M.; Henrissat, B.; Heath, A. C.; Knight, R.; Gordon, J. I. A core gut microbiome in obese and lean twins. Nature, 2009, 457, 480-484.
28. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K. S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; Mende, D. R.; Li, J.; Xu, J.; Li, S.; Li, D.; Cao, J.; Wang, B.; Liang, H.; Zheng, H.; Xie, Y.; Tap, J.; Lepage, P.; Bertalan, M.; Batto, J. M.; Hansen, T.; Le Paslier, D.; Linneberg, A.; Nielsen, H. B.; Pelletier, E.; Renault, P.; Sicheritz-Ponten, T.; Turner, K.; Zhu, H.; Yu, C.; Li, S.; Jian, M.; Zhou, Y.; Li, Y.; Zhang, X.; Li, S.; Qin, N.; Yang, H.; Wang, J.; Brunak, S.; Dore, J.; Guarner, F.; Kristiansen, K.; Pedersen, O.; Parkhill, J.; Weissenbach, J.; Meta-HIT Consortium; Bork, P.; Ehrlich, S. D.; Wang, J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature, 2010, 464, 59-65.
29. Sekirov, I.; Russell, S. L.; Antunes, L. C.; Finlay, B. B. Gut microbiota in health and disease. Physiol. Rev., 2010, 90, 859-904.
30. Nicholson, J. K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. Science, 2012, 336, 1262-1267.
31. Flint, H. J.; Scott, K. P.; Louis, P.; Duncan, S. H. The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol., 2012, 9, 577-589.
32. Hildebrandt, M. A.; Hoffmann, C.; Sherrill-Mix, S. A.; Keilbaugh, S. A.; Hamady, M.; Chen, Y. Y.; Knight, R.; Ahima, R. S.; Bush man, F.; Wu, G. D. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology, 2009, 137, 1716-24.e1-2.
33. Turnbaugh, P. J.; Backhed, F.; Fulton, L.; Gordon, J. I. Dietinduced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. Cell. Host Microbe, 2008, 3, 213-223.
34. Devkota, S.; Wang, Y.; Musch, M. W.; Leone, V.; Fehlner-Peach, H.; Nadimpalli, A.; Antonopoulos, D. A.; Jabri, B.; Chang, E. B. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/-mice. Nature, 2012, 487, 104-108.
35. Ananieva, O.; Nilsson, I.; Vorobjova, T.; Uibo, R.; Wadstrom, T. Immune responses to bile-tolerant helicobacter species in patients with chronic liver diseases, a randomized population group, and healthy blood donors. Clin. Diagn. Lab. Immunol., 2002, 9, 1160-1164.
36. Dussurget, O.; Cabanes, D.; Dehoux, P.; Lecuit, M.; Buchrieser, C.; Glaser, P.; Cossart, P. European Listeria Genome Consortium Listeria monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal and hepatic phases of listeriosis. Mol. Microbiol., 2002, 45, 1095-1106.
37. Loubinoux, J.; Bronowicki, J. P.; Pereira, I. A.; Mougenel, J. L.; Faou, A. E. Sulfate-reducing bacteria in human feces and their association with inflammatory bowel diseases. FEMS Microbiol. Ecol., 2002, 40, 107-112.
38. Rowan, F. E.; Docherty, N. G.; Coffey, J. C.; O'Connell, P. R. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br. J. Surg., 2009, 96, 151-158.
39. Laue, H.; Denger, K.; Cook, A. M. Taurine reduction in anaerobic respiration of Bilophila wadsworthia RZATAU. Appl. Environ. Microbiol., 1997, 63, 2016-2021.
40. Baron, E. J. Bilophila wadsworthia: a unique Gram-negative anaerobic rod. Anaerobe, 1997, 3, 83-86. (Pubitemid 27423129)
41. Wostmann, B. S.; Wiech, N. L.; Kung, E. Catabolism and elimination of cholesterol in germfree rats. J. Lipid Res., 1966, 7, 77-82.
42. Wostmann, B. S. Intestinal bile acids and cholesterol absorption in the germfree rat. J. Nutr., 1973, 103, 982-990.
43. Miyata, M.; Yamakawa, H.; Hamatsu, M.; Kuribayashi, H.; Takamatsu, Y.; Yamazoe, Y. Enterobacteria modulate intestinal bile acid transport and homeostasis through apical sodium-dependent bile acid transporter (SLC10A2) expression. J. Pharmacol. Exp. Ther., 2011, 336, 188-196.
44. Sayin, S. I.; Wahlstrom, A.; Felin, J.; Jantti, S.; Marschall, H. U.; Bamberg, K.; Angelin, B.; Hyotylainen, T.; Oresic, M.; Backhed, F. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell. Metab., 2013, 17, 225-235.
45. Madsen, D.; Beaver, M.; Chang, L.; Bruckner-Kardoss, E.; Wostmann, B. Analysis of bile acids in conventional and germfree rats. J. Lipid Res., 1976, 17, 107-111.
46. Miyata, M.; Takamatsu, Y.; Kuribayashi, H.; Yamazoe, Y. Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression. J. Pharmacol. Exp. Ther., 2009, 331, 1079-1085.
47. Nauck, M.; Schmidt, W. E.; Ebert, R.; Strietzel, J.; Cantor, P.; Hoffmann, G.; Creutzfeldt, W. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J. Clin. Endocrinol. Metab., 1989, 69, 654-662. (Pubitemid 19221242)
48. Kreymann, B.; Williams, G.; Ghatei, M. A.; Bloom, S. R. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet, 1987, 2, 1300-1304.
49. Beysen, C.; Deines, K. C.; Tsang, E. L.; Murphy, E. J.; Chan, M.; Edmonds, J. M.; Neese, R. A.; Hellerstein, M. K. Colesevelam HCl improves glucose metabolism and increases plasma glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide concentrations in subjects with type 2 diabetes. Diabetologia, 2009, 52, s77.
50. Mortensen, K.; Christensen, L. L.; Holst, J. J.; Orskov, C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul. Pept., 2003, 114, 189-196.
51. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev., 2007, 87, 1409-1439.
52. Herrmann, C.; Goke, R.; Richter, G.; Fehmann, H. C.; Arnold, R.; Goke, B. Glucagon-like peptide-1 and glucose-dependent insulinreleasing polypeptide plasma levels in response to nutrients. Digestion, 1995, 56, 117-126.
53. Holst, J. J.; McGill, M. A. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants. Clin. Drug Investig., 2012, 32, 1-14.
54. Holst, J. J. Enteroglucagon. Annu. Rev. Physiol., 1997, 59, 257-271.
55. Thomas, C.; Gioiello, A.; Noriega, L.; Strehle, A.; Oury, J.; Rizzo, G.; Macchiarulo, A.; Yamamoto, H.; Mataki, C.; Pruzanski, M.; Pellicciari, R.; Auwerx, J.; Schoonjans, K. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab., 2009, 10, 167-177.
56. Patti, M. E.; Houten, S. M.; Bianco, A. C.; Bernier, R.; Larsen, P. R.; Holst, J. J.; Badman, M. K.; Maratos-Flier, E.; Mun, E. C.; Pihlajamaki, J.; Auwerx, J.; Goldfine, A. B. Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism. Obesity, 2009, 17, 1671-1677.
57. Nakatani, H.; Kasama, K.; Oshiro, T.; Watanabe, M.; Hirose, H.; Itoh, H. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism, 2009, 58, 1400-1407.
58. Out, C.; Groen, A. K.; Brufau, G. Bile acid sequestrants: more than simple resins. Curr. Opin. Lipidol., 2012, 23, 43-55.
59. Chen, L.; McNulty, J.; Anderson, D.; Liu, Y.; Nystrom, C.; Bullard, S.; Collins, J.; Handlon, A. L.; Klein, R.; Grimes, A.; Murray, D.; Brown, R.; Krull, D.; Benson, B.; Kleymenova, E.; Remlinger, K.; Young, A.; Yao, X. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like Peptide 1 release in zucker diabetic Fatty rats. J. Pharmacol. Exp. Ther., 2010, 334, 164-170.
60. Shang, Q.; Saumoy, M.; Holst, J. J.; Salen, G.; Xu, G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am. J. Physiol. Gastrointest. Liver Physiol., 2010, 298, G419-G424.
61. Harach, T.; Pols, T. W.; Nomura, M.; Maida, A.; Watanabe, M.; Auwerx, J.; Schoonjans, K. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep., 2012, 2, 430.
62. Chen, L.; Yao, X.; Young, A.; McNulty, J.; Anderson, D.; Liu, Y.; Nystrom, C.; Croom, D.; Ross, S.; Collins, J.; Rajpal, D.; Hamlet, K.; Smith, C.; Gedulin, B. Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes. Am. J. Physiol. Endocrinol. Metab., 2012, 302, E68-76.
63. Gioiello, A.; Rosatelli, E.; Nuti, R.; Macchiarulo, A.; Pellicciari, R. Patented TGR5 modulators: a review (2006-present). Expert Opin. Ther. Pat., 2012, 22, 1399-1414.
64. Anderson, S. L.; Trujillo, J. M. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann. Pharmacother., 2010, 44, 904-909.
65. Marguet, D.; Baggio, L.; Kobayashi, T.; Bernard, A. M.; Pierres, M.; Nielsen, P. F.; Ribel, U.; Watanabe, T.; Drucker, D. J.; Wagtmann, N. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA, 2000, 97, 6874-6879.
66. Park, H.; Park, C.; Kim, Y.; Rascati, K. L. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann. Pharmacother., 2012, 46, 1453-1469.
67. Watanabe, M.; Houten, S.; Mataki, C.; Christoffolete, M.; Kim, B.; Sato, H.; Messaddeq, N.; Harney, J.; Ezaki, O.; Kodama, T.; Schoonjans, K.; Bianco, A.; Auwerx, J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature, 2006, 439, 484-489. (Pubitemid 43152840)
68. Houten, S. M.; Watanabe, M.; Auwerx, J. Endocrine functions of bile acids. EMBO J., 2006, 25, 1419-1425.
69. Tomlinson, E.; Fu, L.; John, L.; Hultgren, B.; Huang, X.; Renz, M.; Stephan, J. P.; Tsai, S. P.; Powell-Braxton, L.; French, D.; Stewart, T. A. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology, 2002, 143, 1741-1747. (Pubitemid 34415889)
70. Watanabe, M.; Horai, Y.; Houten, S. M.; Morimoto, K.; Sugizaki, T.; Arita, E.; Mataki, C.; Sato, H.; Tanigawara, Y.; Schoonjans, K.; Itoh, H.; Auwerx, J. Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure. J. Biol. Chem., 2011, 286, 26913-26920.
71. Ockenga, J.; Valentini, L.; Schuetz, T.; Wohlgemuth, F.; Glaeser, S.; Omar, A.; Kasim, E.; duPlessis, D.; Featherstone, K.; Davis, J. R.; Tietge, U. J.; Kroencke, T.; Biebermann, H.; Kohrle, J.; Brabant, G. Plasma bile acids are associated with energy expenditure and thyroid function in humans. J. Clin. Endocrinol. Metab., 2012, 97, 535-542.
72. Brufau, G.; Bahr, M. J.; Staels, B.; Claudel, T.; Ockenga, J.; Boker, K. H.; Murphy, E. J.; Prado, K.; Stellaard, F.; Manns, M. P.; Kuipers, F.; Tietge, U. J. Plasma bile acids are not associated with energy metabolism in humans. Nutr. Metab. (Lond.), 2010, 7, 73.
73. Kim, I.; Ahn, S. H.; Inagaki, T.; Choi, M.; Ito, S.; Guo, G. L.; Kliewer, S. A.; Gonzalez, F. J. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res., 2007, 48, 2664-2672. (Pubitemid 350272851)
74. Wang, Y. D.; Chen, W. D.; Wang, M.; Yu, D.; Forman, B. M.; Huang, W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology, 2008, 48, 1632-1643.
75. Renga, B.; Migliorati, M.; Mencarelli, A.; Fiorucci, S. Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma- STAT-1 pathway in macrophages. Biochim. Biophys. Acta, 2009, 1792, 564-573.
76. Inagaki, T.; Moschetta, A.; Lee, Y. K.; Peng, L.; Zhao, G.; Downes, M.; Yu, R. T.; Shelton, J. M.; Richardson, J. A.; Repa, J. J.; Mangelsdorf, D. J.; Kliewer, S. A. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. USA, 2006, 103, 3920-3925.
77. Gadaleta, R. M.; van Erpecum, K. J.; Oldenburg, B.; Willemsen, E. C.; Renooij, W.; Murzilli, S.; Klomp, L. W.; Siersema, P. D.; Schipper, M. E.; Danese, S.; Penna, G.; Laverny, G.; Adorini, L.; Moschetta, A.; van Mil, S. W. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut, 2011, 60, 463-472.
78. Vavassori, P.; Mencarelli, A.; Renga, B.; Distrutti, E.; Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol., 2009, 183, 6251-6261.
79. Gadaleta, R. M.; Oldenburg, B.; Willemsen, E. C.; Spit, M.; Murzilli, S.; Salvatore, L.; Klomp, L. W.; Siersema, P. D.; van Erpecum, K. J.; van Mil, S. W. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NFkappaB signaling in the intestine. Biochim. Biophys. Acta, 2011, 1812, 851-858.
80. Hollman, D. A.; Milona, A.; van Erpecum, K. J.; van Mil, S. W. Anti-inflammatory and metabolic actions of FXR: Insights into molecular mechanisms. Biochim. Biophys. Acta, 2012, 1821, 1443-1452.
81. Magyar, I.; Loi, H. G.; Feher, T. Plasma bile acid levels and liver disease. Acta Med. Acad. Sci. Hung., 1981, 38, 109-115.
82. Kirby, J.; Heaton, K. W.; Burton, J. L. Pruritic effect of bile salts. Br. Med. J., 1974, 4, 693-695.
83. Mela, M.; Mancuso, A.; Burroughs, A. K. Review article: pruritus in cholestatic and other liver diseases. Aliment. Pharmacol. Ther., 2003, 17, 857-870.
84. Alemi, F.; Kwon, E.; Poole, D. P.; Lieu, T.; Lyo, V.; Cattaruzza, F.; Cevikbas, F.; Steinhoff, M.; Nassini, R.; Materazzi, S.; Guerrero-Alba, R.; Valdez-Morales, E.; Cottrell, G. S.; Schoonjans, K.; Geppetti, P.; Vanner, S. J.; Bunnett, N. W.; Corvera, C. U. The TGR5 receptor mediates bile acid-induced itch and analgesia. J. Clin. Invest., 2013, 123, 1513-1530.
85. Kremer, A. E.; van Dijk, R.; Leckie, P.; Schaap, F. G.; Kuiper, E. M.; Mettang, T.; Reiners, K. S.; Raap, U.; van Buuren, H. R.; van Erpecum, K. J.; Davies, N. A.; Rust, C.; Engert, A.; Jalan, R.; Oude Elferink, R. P.; Beuers, U. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology, 2012, 56, 1391-1400.
86. Poole, D. P.; Godfrey, C.; Cattaruzza, F.; Cottrell, G. S.; Kirkland, J. G.; Pelayo, J. C.; Bunnett, N. W.; Corvera, C. U. Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system. Neurogastroenterol. Motil., 2010, 22, 814-825, e227-8.
87. Schirra, J.; Nicolaus, M.; Roggel, R.; Katschinski, M.; Storr, M.; Woerle, H. J.; Goke, B. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut, 2006, 55, 243-251. (Pubitemid 43117285)
88. Herrema, H.; Meissner, M.; van Dijk, T. H.; Brufau, G.; Boverhof, R.; Oosterveer, M. H.; Reijngoud, D. J.; Muller, M.; Stellaard, F.; Groen, A. K.; Kuipers, F. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor-and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology, 2010, 51, 806-816.
89. Hambruch, E.; Miyazaki-Anzai, S.; Hahn, U.; Matysik, S.; Boettcher, A.; Perovic-Ottstadt, S.; Schluter, T.; Kinzel, O.; Krol, H. D.; Deuschle, U.; Burnet, M.; Levi, M.; Schmitz, G.; Miyazaki, M.; Kremoser, C. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice. J. Pharmacol. Exp. Ther., 2012, 343, 556-567.